Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company. The Company develops and commercializes therapeutics and medicines for the treatments and preventions for viral and bacterial diseases. Vir Biotechnology serves customers in the State of California.
Website: vir.bio



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 128.2%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +75.8%. On average the margin is improving steadily. Gross margin is high, +92.7%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of +$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 40.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 74.1% higher than minimum and 72.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued >100x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $5.7 mln (-0.692% of cap.)

Key Financials (Download financials)

Ticker: VIR
Share price, USD:  (0.0%)7.45
year average price 5.98  


year start price 10.02 2025-02-08

max close price 10.02 2025-02-08

min close price 4.28 2025-08-11

current price 7.45 2026-02-07
Common stocks: 132 606 767

Dividend Yield:  0.0%
FCF Yield LTM: 40.9%
EV / LTM EBITDA: 500.0x
EV / Sales: 0.0x
Margin (EBITDA LTM / Revenue): 75.8%
Fundamental value created in LTM:
Market Cap ($m): 988
Net Debt ($m): -1 077
EV (Enterprise Value): -89
Price to Book: 1.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-15seekingalpha.com

Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-11-05seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript

2025-10-09zacks.com

Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?

2025-09-16seekingalpha.com

Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-08-06seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

2025-08-06zacks.com

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

2025-07-23seekingalpha.com

Vir Biotechnology: Hep B And Cancer Projects March On

2025-05-07seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

2025-02-26seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

2025-01-09zacks.com

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-06 2024-11-04 2024-08-01 2024-05-03 2023-11-03 2023-08-04 2023-05-08 2022-11-03
acceptedDate 2025-11-05 17:15:30 2025-08-06 17:31:25 2025-02-26 17:34:44 2024-11-04 16:09:50 2024-08-01 16:43:21 2024-05-03 16:16:53 2024-02-26 16:10:13 2023-11-03 16:05:44 2023-08-04 16:02:43 2023-05-08 16:06:26 2023-02-28 16:22:13 2022-11-03 16:08:24 2022-02-28 16:16:17 2021-02-25 16:57:12
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 240 000 1M 74M 2M 3M 56M 86M -4M -13M 47M 1 616M 371M 1 095M 67M
costOfRevenue 151M 98M 479M 50 000 4M 5M 573M 38 000 22 000 2M 621M 22M 514M 0
grossProfit -151M -96M -404M 2M -1M 52M -487M -4M -13M 45M 995M 349M 582M 67M
grossProfitRatio -630.05 -79.329 0.979 -0.402 0.919 1.009 1.002 0.959 0.94
researchAndDevelopmentExpenses 151M 98M 506M 195M 98M 68M 580M 148M 172M 158M 475M 114M 448M 302M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 71M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 22M 0 0 26M 30M 36M 0 41M 47M 47M 0 43M 0 71M
otherExpenses -151M -75M -324M 11M -535 000 -287 000 -382M 882 000 -367 000 -16M -313M -3M -287M -9M
operatingExpenses 22M 22M 183M 234M 128M 104M 198M 183M 202M 188M 162M 154M 161M 364M
costAndExpenses 174M 120M 661M 232M 132M 109M 770M 183M 202M 190M 783M 176M 675M 364M
interestIncome 9M 11M 72M 18M 19M 21M 87M 22M 23M 21M 28M 9M 439 000 3M
interestExpense 0 0 0 0 0 0 0 0 0 -239 000 0 9M 0 0
depreciationAndAmortization 3M 3M 15M 3M 4M 5M 19M 3M 5M 13M 7M 14M 6M 5M
ebitda -160M -116M -509M -216M -128M -48M -642M -184M -210M -130M 840M 209M 427M -292M
ebitdaratio -666.563 -95.282 -90.629 -40.685 -0.851 44.906 16.515 -2.789 0.561
operatingIncome -173M -118M -587M -219M -129M -52M -684M -187M -215M -143M 833M 195M 421M -297M
operatingIncomeRatio -722.679 -97.543 -91.845 -42.07 -0.931 45.567 16.914 -3.069 0.525
totalOtherIncomeExpensesNet 10M 8M 64M 5M 19M -13M 56M -2M -5M 183 000 -79M 23M 129M -2M
incomeBeforeTax -163M -111M -523M -214M -140M -65M -628M -167M -198M -143M 754M 218M 550M -299M
incomeBeforeTaxRatio -679.054 -91.259 -89.723 -45.493 -1.153 40.66 15.534 -3.065 0.586
incomeTaxExpense 168 000 170 000 -1M 177 000 -2M 276 000 -13M -3M -3M -2M 238M 42M 21M 54 000
netIncome -163M -111M -522M -214M -138M -65M -615M -163M -195M -141M 516M 175M 529M -299M
netIncomeRatio -679.754 -91.399 -89.797 -45.001 -1.158 39.876 15.31 -3.018 0.472
eps -1.17 -0.8 -3.83 -1.56 -1.02 -0.48 -4.59 -1.22 -1.45 -1.06 3.89 1.32 4.07 -2.51
epsdiluted -1.17 -0.8 -1.56 -1.02 -0.48 -1.22 -1.45 -1.06 1.3
weightedAverageShsOut 139M 138M 136M 137M 136M 135M 134M 134M 134M 134M 133M 133M 130M 119M
weightedAverageShsOutDil 139M 138M 136M 137M 136M 135M 134M 134M 134M 134M 135M 135M 133M 119M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-26 2023-02-28 2022-02-28 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 72M 87M 28M 439 000 3M
ebit -523M -661M 833M 421M -297M
nonOperatingIncomeExcludingInterest -64M -23M 0 0 0
netIncomeFromContinuingOperations -522M -615M 516M 529M -299M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -522M -615M 516M 529M -299M
epsDiluted -3.83 -4.59 3.83 3.96 -2.51

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-06 2024-11-04 2024-08-01 2024-05-03 2023-11-03 2023-08-04 2023-05-08 2022-11-03
acceptedDate 2025-11-05 17:15:30 2025-08-06 17:31:25 2025-02-26 17:34:44 2024-11-04 16:09:50 2024-08-01 16:43:21 2024-05-03 16:16:53 2024-02-26 16:10:13 2023-11-03 16:05:44 2023-08-04 16:02:43 2023-05-08 16:06:26 2023-02-28 16:22:13 2022-11-03 16:08:24 2022-02-28 16:16:17 2021-02-25 16:57:12
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 170M 211M 223M 168M 311M 174M 242M 452M 667M 825M 849M 964M 348M 437M
shortTermInvestments 336M 395M 682M 746M 854M 989M 1 281M 1 244M 1 180M 1 425M 1 553M 1 383M 360M 300M
cashAndShortTermInvestments 507M 606M 905M 999M 1 165M 1 163M 1 522M 1 697M 1 847M 2 250M 2 402M 2 346M 708M 737M
netReceivables 0 0 0 0 7M 10M 0 5M 0 0 0 0 773M 0
inventory 0 0 0 0 1 0 0 8M 0 0 0 0 0 0
otherCurrentAssets 39M 130M 137M 49M 79M 40M 66M 59M 86M 98M 59M 67M 9M 8M
totalCurrentAssets 546M 736M 1 042M 1 047M 1 206M 1 213M 1 588M 1 769M 1 946M 2 359M 2 519M 2 414M 1 563M 772M
propertyPlantEquipmentNet 122M 126M 123M 126M 128M 163M 167M 172M 179M 185M 188M 185M 130M 80M
goodwill 17M 17M 17M 17M 17M 17M 17M 17M 17M 17M 17M 17M 17M 17M
intangibleAssets 8M 8M 8M 19M 19M 22M 23M 25M 26M 33M 33M 33M 33M 34M
goodwillAndIntangibleAssets 25M 25M 25M 36M 36M 39M 40M 42M 43M 50M 50M 50M 50M 51M
longTermInvestments 304M 286M 190M 278M 286M 366M 105M 40M 52M 49M 24M 34M 201M 0
taxAssets 0 0 0 0 0 0 0 0 0 0 250M 0 0 0
otherNonCurrentAssets 23M 20M 18M 12M 13M 12M 19M 22M 24M 23M -228M 13M 10M 16M
totalNonCurrentAssets 474M 457M 356M 451M 464M 581M 331M 276M 298M 307M 283M 282M 391M 146M
otherAssets 0 0 22 000 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 019M 1 193M 1 399M 1 498M 1 670M 1 794M 1 919M 2 045M 2 244M 2 666M 2 802M 2 696M 1 954M 919M
accountPayables 7M 12M 5M 7M 4M 7M 6M 4M 12M 12M 6M 3M 7M 5M
shortTermDebt 9M 9M 0 19M 19M 12M 0 14M 14M 7M 0 4M 0 0
taxPayables 0 0 0 0 17 000 146 000 149 000 15M 15M 15M 15M 98M 6M 0
deferredRevenue 0 10M 13M 15M 17M 15M 65M 15M 16M 17M 16M 23M 98M 6M
otherCurrentLiabilities 59M 74M 16M 75M 56M 60M 9M 133M 184M 449M 8M 279M 0 11M
totalCurrentLiabilities 75M 105M 120M 117M 96M 94M 175M 165M 226M 485M 511M 308M 341M 99M
longTermDebt 91M 93M 0 187M 95M 109M 0 114M 118M 121M 0 127M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 2M 2M 53M 53M 53M 53M 55M 4M 4M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 3M 3M 18M 18M 3M
otherNonCurrentLiabilities 57M 47M 39M -46M 44M 42M 40M 37M 37M 32M 33M 208M 25M 29M
totalNonCurrentLiabilities 148M 140M 129M 140M 139M 153M 153M 205M 208M 210M 213M 238M 181M 103M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 100M 102M 98M 113M 115M 109M 125M 114M 118M 121M 128M 127M 137M 70M
totalLiabilities 223M 245M 248M 258M 236M 247M 329M 370M 434M 695M 724M 546M 522M 202M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 14 000 14 000 14 000 14 000 14 000 14 000 13 000 13 000 13 000 13 000 13 000 13 000 13 000 13 000
retainedEarnings -1 155M -992M -760M -655M -441M -303M -238M -122M 42M 236M 377M 479M -139M -667M
accumulatedOtherComprehensiveIncomeLoss -2M -2M -2M 1M -3M -2M -815 000 -2M -3M -3M -9M -12M -1M -1M
othertotalStockholdersEquity 1 953M 1 941M 1 895M 1 878M 1 853M 1 799M 1 772M 1 738M 1 683M
totalStockholdersEquity 796M 947M 1 150M 1 241M 1 434M 1 547M 1 590M 1 675M 1 810M 1 971M 2 078M 2 150M 1 432M 717M
totalEquity 796M 947M 1 150M 1 241M 1 434M 1 547M 1 590M 1 675M 1 810M 1 971M 2 078M 2 150M 1 432M 717M
totalLiabilitiesAndStockholdersEquity 1 019M 1 193M 1 498M 1 670M 1 794M 2 045M 2 244M 2 666M 2 696M
minorityInterest 0 0 0 0 0 0 0 0 0 44 000 0 0 0 0
totalLiabilitiesAndTotalEquity 1 019M 1 193M 1 399M 1 498M 1 670M 1 794M 1 919M 2 045M 2 244M 2 666M 2 802M 2 696M 1 954M 919M
totalInvestments 641M 681M 872M 1 024M 1 141M 1 355M 1 386M 1 273M 1 219M 1 456M 1 577M 1 417M 562M 300M
totalDebt 100M 102M 98M 113M 115M 121M 125M 114M 118M 121M 128M 127M 137M 70M
netDebt -70M -109M -125M -56M -196M -53M -117M -338M -549M -703M -721M -837M -210M -366M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-26 2023-02-28 2022-02-28 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 773M 0
prepaids 0 0 58M 73M 28M
totalPayables 17M 6M 22M 110M 9M
otherPayables 12M 0 15M 103M 3M
accruedExpenses 67M 82M 462M 130M 70M
capitalLeaseObligationsCurrent 8M 13M 4M 4M 4M
capitalLeaseObligationsNonCurrent 90M 112M 124M 134M 67M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 912M 1 829M 1 710M 1 572M 1 385M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR VIR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-06 2024-11-04 2024-08-01 2024-05-03 2023-11-03 2023-08-04 2023-05-08 2022-11-03
acceptedDate 2025-11-05 17:15:30 2025-08-06 17:31:25 2025-02-26 17:34:44 2024-11-04 16:09:50 2024-08-01 16:43:21 2024-05-03 16:16:53 2024-02-26 16:10:13 2023-11-03 16:05:44 2023-08-04 16:02:43 2023-05-08 16:06:26 2023-02-28 16:22:13 2022-11-03 16:08:24 2022-02-28 16:16:17 2021-02-25 16:57:12
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -163M -111M -522M -214M -138M -65M -615M -163M -195M -141M 516M 175M 529M -299M
depreciationAndAmortization 3M 10M 15M 3M 4M 5M 19M 5M 5M 6M 7M 2M 6M 5M
deferredIncomeTax 0 0 -3M 57 000 -363 000 0 -1M -167M 14M 0 -15M 0 15M -52 000
stockBasedCompensation 0 12M 78M 17M 22M 24M 0 27M 31M 25M 102M 25M 84M 28M
changeInWorkingCapital -21M -25M -84M 17M -2M -82M -305M -30M -253M 11M 665M -55M -628M 30M
accountsReceivables 0 0 -7M -2M 3M -401 000 -565 000 -3M 948 000 2M 770M 58M -773M 0
inventory 0 0 0 0 0 0 0 3M -251M 0 0 0 53M 0
accountsPayables -5M 9M -988 000 3M -3M 735 000 732 000 -8M -934 000 7M 797 000 -4M -171 000 -790 000
otherWorkingCapital -15M -34M -77M 17M -2M -82M -305M -22M -2M 2M -105M -109M 92M 30M
otherNonCashItems 13M -6M 70M 5M 68M 42M 122M 172M 9M -27M 388M -29M -53M 45M
netCashProvidedByOperatingActivities -168M -120M -446M -171M -78M -109M -779M -156M -389M -126M 1 663M 118M -48M -191M
investmentsInPropertyPlantAndEquipment -317 000 -3M -7M -2M -666 000 -2M -22M -4M -9M -7M -68M -19M -22M -7M
acquisitionsNet 37 000 0 3M -912 000 379 000 533 000 100 000 55M 0 0 0 0 141M 0
purchasesOfInvestments -264M -192M -1 235M -240M -271M -563M -2 016M -503M -310M -385M -1 477M -728M -420M -404M
salesMaturitiesOfInvestments 305M 251M 1 739M 362M 483M 593M 2 202M 448M 550M 489M 352M 85M 301M 400M
otherInvestingActivites 0 45 000 505 000 212M 533 000 -55M 0 0 11 000
netCashUsedForInvestingActivites 40M 56M 119M 212M 28M -59M 230M 98M -663M
debtRepayment 0 0 -40 000 -69 000 -69 000 -66 000 -68 000 -66 000 -59 000
commonStockIssued 101 000 2M 71 000 3M 221 000 343 000 0 2M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 1000 -360 000 71 000 3M 221 000 277 000 3M 100 000 2M
netCashUsedProvidedByFinancingActivities 102 000 2M 31 000 3M 152 000 277 000 3M 2M 2M
effectOfForexChangesOnCash -1000 0 0 0 0 0 208 000 48M 0 0 0 0 0 0
netChangeInCash -127M -62M 57M -46M 137M -81M -606M -215M -156M -25M 505M -543M -88M 329M
cashAtEndOfPeriod 172M 306M 319M 264M 311M 174M 255M 472M 687M 843M 868M 984M 363M 451M
cashAtBeginningOfPeriod 299M 368M 261M 311M 174M 255M 861M 687M 843M 868M 363M 1 527M 451M 123M
operatingCashFlow -168M -120M -446M -171M -78M -109M -779M -156M -389M -126M 1 663M 118M -48M -191M
capitalExpenditure -317 000 -3M -7M -2M -666 000 -2M -22M -4M -9M -7M -68M -19M -22M -7M
freeCashFlow -168M -123M -454M -174M -79M -111M -800M -160M -399M -133M 1 595M 99M -69M -197M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-26 2023-02-28 2022-02-28 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 -141M 180 000
netCashProvidedByInvestingActivities 499M 165M -1 193M -141M -10M
netDebtIssuance -165 000 -287 000 -260 000 -259 000 -250 000
longTermNetDebtIssuance -165 000 -287 000 -260 000 -259 000 -250 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 5M 8M 28M 85M 530M
netCommonStockIssuance 5M 8M 28M 85M 530M
commonStockIssuance 5M 8M 28M 85M 530M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 -100 000 7M 15M -189 000
netCashProvidedByFinancingActivities 4M 7M 35M 100M 529M
incomeTaxesPaid 786 000 0 252M 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-05 ET (fiscal 2025 q3)
2025 q2
2025-08-06 ET (fiscal 2025 q2)
2025 q1
2025-05-07 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-03 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)

SEC forms

Show financial reports only

SEC form 8
2026-01-12 13:07 ET
Vir Biotechnology published news for 2025 q4
SEC form 8
2026-01-12 13:07 ET
Vir Biotechnology published news for 2025 q4
SEC form 8
2026-01-12 13:07 ET
Vir Biotechnology published news for 2025 q4
SEC form 8
2025-12-16 21:25 ET
Vir Biotechnology published news for 2025 q3
SEC form 8
2025-12-16 21:25 ET
Vir Biotechnology published news for 2025 q3
SEC form 10
2025-11-05 22:15 ET
Vir Biotechnology reported for 2025 q3
SEC form 8
2025-11-05 21:12 ET
Vir Biotechnology published news for 2025 q3
SEC form 8
2025-11-05 21:12 ET
Vir Biotechnology reported for 2025 q3
SEC form 10
2025-08-06 21:31 ET
Vir Biotechnology reported for 2025 q2
SEC form 8
2025-08-06 20:09 ET
Vir Biotechnology published news for 2025 q2
SEC form 8
2025-08-06 20:09 ET
Vir Biotechnology reported for 2025 q2
SEC form 8
2025-07-24 13:05 ET
Vir Biotechnology published news for 2025 q2
SEC form 8
2025-07-24 13:05 ET
Vir Biotechnology published news for 2025 q2
SEC form 8
2025-05-09 12:23 ET
Vir Biotechnology published news for 2025 q1
SEC form 8
2025-05-09 12:23 ET
Vir Biotechnology published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Vir Biotechnology published news for 2025 q1
SEC form 10
2025-05-07 21:33 ET
Vir Biotechnology published news for 2025 q1
SEC form 8
2025-05-07 20:13 ET
Vir Biotechnology published news for 2025 q1
SEC form 8
2025-05-07 20:13 ET
Vir Biotechnology reported for 2025 q1
SEC form 10
2025-02-27 00:00 ET
Vir Biotechnology published news for 2024 q4
SEC form 10
2025-02-26 22:34 ET
Vir Biotechnology published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Vir Biotechnology published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Vir Biotechnology reported for 2024 q4
SEC form 10
2024-11-04 16:09 ET
Vir Biotechnology reported for 2024 q3
SEC form 8
2024-10-31 16:20 ET
Vir Biotechnology published news for 2024 q3
SEC form 8
2024-10-31 16:20 ET
Vir Biotechnology reported for 2024 q3
SEC form 10
2024-08-01 16:43 ET
Vir Biotechnology reported for 2024 q2
SEC form 8
2024-08-01 16:10 ET
Vir Biotechnology published news for 2024 q2
SEC form 8
2024-08-01 16:10 ET
Vir Biotechnology reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Vir Biotechnology reported for 2024 q2
SEC form 10
2024-05-03 16:16 ET
Vir Biotechnology published news for 2024 q1
SEC form 10
2024-05-03 00:00 ET
Vir Biotechnology published news for 2024 q1
SEC form 8
2024-05-02 16:09 ET
Vir Biotechnology published news for 2024 q1
SEC form 8
2024-05-02 16:09 ET
Vir Biotechnology reported for 2024 q1
SEC form 10
2024-02-26 00:00 ET
Vir Biotechnology published news for 2023 q4
SEC form 10
2023-11-03 16:05 ET
Vir Biotechnology reported for 2023 q3
SEC form 10
2023-11-03 00:00 ET
Vir Biotechnology reported for 2023 q3
SEC form 8
2023-11-02 16:09 ET
Vir Biotechnology reported for 2023 q3
SEC form 10
2023-08-04 16:02 ET
Vir Biotechnology reported for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Vir Biotechnology reported for 2023 q2
SEC form 6
2023-08-03 16:14 ET
Vir Biotechnology reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Vir Biotechnology reported for 2023 q2
SEC form 6
2023-07-20 08:04 ET
Vir Biotechnology published news for 2023 q2
SEC form 8
2023-07-20 00:00 ET
Vir Biotechnology published news for 2023 q2
SEC form 10
2023-05-08 00:00 ET
Vir Biotechnology reported for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Vir Biotechnology reported for 2023 q1
SEC form 6
2023-03-10 21:45 ET
Vir Biotechnology published news for 2022 q4
SEC form 6
2023-03-08 16:06 ET
Vir Biotechnology published news for 2022 q4
SEC form 10
2023-02-28 16:22 ET
Vir Biotechnology reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Vir Biotechnology reported for 2022 q4
SEC form 6
2023-02-23 16:05 ET
Vir Biotechnology reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Vir Biotechnology reported for 2022 q4
SEC form 6
2023-02-22 08:41 ET
Vir Biotechnology published news for 2022 q4
SEC form 6
2023-02-16 08:36 ET
Vir Biotechnology published news for 2022 q4
SEC form 6
2023-02-13 16:31 ET
Vir Biotechnology published news for 2022 q4
SEC form 6
2023-01-25 08:33 ET
Vir Biotechnology published news for 2022 q4
SEC form 10
2022-11-03 16:08 ET
Vir Biotechnology reported for 2022 q3
SEC form 6
2022-11-03 16:06 ET
Vir Biotechnology reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Vir Biotechnology reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Vir Biotechnology reported for 2022 q3
SEC form 6
2022-10-04 08:23 ET
Vir Biotechnology published news for 2022 q3
SEC form 10
2022-08-09 16:12 ET
Vir Biotechnology published news for 2022 q2
SEC form 6
2022-08-09 16:08 ET
Vir Biotechnology reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Vir Biotechnology published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Vir Biotechnology reported for 2022 q2
SEC form 6
2022-08-04 08:07 ET
Vir Biotechnology published news for 2022 q2
SEC form 6
2022-07-14 08:34 ET
Vir Biotechnology published news for 2022 q2
SEC form 6
2022-06-03 16:06 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-05-24 16:07 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-05-20 16:06 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-05-05 16:09 ET
Vir Biotechnology published news for 2022 q1
SEC form 10
2022-05-05 16:07 ET
Vir Biotechnology reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Vir Biotechnology reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Vir Biotechnology reported for 2022 q1
SEC form 6
2022-04-07 16:08 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-04-07 16:06 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-04-05 17:19 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-03-25 16:10 ET
Vir Biotechnology published news for 2021 q4
SEC form 10
2022-02-28 16:16 ET
Vir Biotechnology published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Vir Biotechnology published news for 2021 q4
SEC form 6
2022-02-24 16:27 ET
Vir Biotechnology published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Vir Biotechnology published news for 2021 q4
SEC form 6
2021-12-22 16:06 ET
Vir Biotechnology published news for 2021 q3
SEC form 10
2021-11-04 16:08 ET
Vir Biotechnology published news for 2021 q3
SEC form 6
2021-11-04 16:07 ET
Vir Biotechnology published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Vir Biotechnology published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Vir Biotechnology published news for 2021 q3
SEC form 6
2021-09-29 17:13 ET
Vir Biotechnology published news for 2021 q2
SEC form 10
2021-08-05 16:16 ET
Vir Biotechnology published news for 2021 q2
SEC form 6
2021-08-05 16:14 ET
Vir Biotechnology published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Vir Biotechnology published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Vir Biotechnology published news for 2021 q2
SEC form 6
2021-06-28 06:07 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-05-27 16:55 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-05-24 17:00 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-05-21 15:38 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-05-06 16:24 ET
Vir Biotechnology published news for 2021 q1
SEC form 10
2021-05-06 16:06 ET
Vir Biotechnology published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Vir Biotechnology published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-04-13 16:06 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-04-06 16:05 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-03-31 16:05 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-03-30 06:07 ET
Vir Biotechnology published news for 2020 q4
SEC form 10
2021-02-25 16:57 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-02-25 16:15 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-02-19 17:03 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-01-28 16:05 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-01-06 17:16 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2020-12-29 16:00 ET
Vir Biotechnology published news for 2020 q3
SEC form 6
2020-12-10 17:21 ET
Vir Biotechnology published news for 2020 q3
SEC form 6
2020-11-10 17:16 ET
Vir Biotechnology published news for 2020 q3
SEC form 10
2020-11-10 16:13 ET
Vir Biotechnology published news for 2020 q3
SEC form 6
2020-11-10 16:05 ET
Vir Biotechnology published news for 2020 q3